An interventional study of 10% Velocity-Loss Threshold Resistance Training and 30% Velocity-Loss Threshold Resistance Training in Activity, Motor, sponsored by University of Miami. Recruiting at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by University of Miami · Not applicable, Interventional, and Treatment
Among 25 studies in Motor Activity by University of Miami — 10 open to participants now, 10 under way, none of them phase 3. Motor Activity · University of Miami.
Among the 25 studies in Motor Activity by University of Miami, this one is the 10th largest by planned enrollment, is one of 7 that started in 2026, is one of 24 with no phase, and was the 25th registered.
9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.
This study's planned enrollment of 60 is close to the median of 60 across 8,388 interventional studies indexed under Motor Activity.
Browse Motor Activity studies →10 of the 25 studies in Motor Activity by University of Miami are open now, in 1 country. Each count lists the studies.
Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →25 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 7 started in 2026.
Median enrollment 50 across the 25 interventional studies. Of the 15 that completed or were terminated, 3 (20%) have results posted.
University of Miami is the lead sponsor of 840 studies on the registry; 164 are open to participants now.
Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.
4 of the studies in Motor Activity by University of Miami that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07840508University of MiamiVelocity-Loss Training and Parkinson's Disease | 2026-12-30 |
| NCT06512675University of MiamiEffects of an Exercise Program on Reaction Time and Mouse Accuracy in Recreational Video Game Players | 2027-05-01 |
| NCT07378813University of MiamiLow Versus High Load Training and Parkinson's Disease | 2027-05-30 |
| NCT07378826University of MiamiPower Training Progression Methods | 2027-05-30 |
Among the 25 studies in Motor Activity by University of Miami, from their registry updates:
This study will compare the effects of velocity-loss resistance training at 10% and 30% velocity loss thresholds on measures of muscle strength and power and tests of daily performance in older adults with Parkinson's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive velocity-based resistance training at 10% velocity-loss threshold, twice per week for at least 24 sessions for up to 12 weeks.
Behavioral: 10% Velocity-Loss Threshold Resistance Training
Participants will receive velocity-based resistance training at 30% velocity-loss threshold, twice per week for at least 24 sessions for up to 12 weeks.
Behavioral: 30% Velocity-Loss Threshold Resistance Training
Participants will receive a total of twenty-four 45-minutes in-person training sessions at 10% velocity-loss threshold, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include four upper-body exercises and 2 lower-body exercises.
Participants will receive a total of twenty-four 45-minutes in-person training sessions at 30% velocity-loss threshold, twice per week using three sets of eight repetitions per set. During training participants will be allowed 1-minute rests between sets. Exercises will include four upper-body exercises and 2 lower-body exercises.
Change in neuromuscular performance as measured by 1-repetition maximum (1RM)
Maximal load that can be lifted in one repetition (1RM) will be assessed in both leg press and chest press exercises. The loads on the testing equipment will be increased across 5 to 7 testing repetitions. The persons 1RM will be the highest load the person can move through the range of motion of the exercise. There are no minimum or maximum scores for this test. The higher the 1RM the stronger the person is. The unit of measurement is kilograms.
Time frame: Baseline, 12 weeks
Change in neuromuscular performance as measured by Watts
This test measures the power a person can produce at maximal speed using loads of 20%, 40%, 60%, 80%, and 90% of 1RM for the chest press and leg press. Power shows how fast a person can do work. There are no minimum or maximum possible values. Higher values indicate better neuromuscular performance. Unit of measure is Watts.
Time frame: Baseline, 12 weeks
Change in the Speed of the Ten-Meter Walk Test.
The ten-meter walk test will be used to assess gait velocity. The participants will be asked to walk at usual walking speed and as quickly as possible in a straight line on a 10-meter (m) course marked at 0, 2, 8 and 10 m. On verbal command, participants will start on the 0-m mark and stop when the 10-m mark is crossed. The total time to ambulate from the 2-m mark to the 8-m mark (6 m total) will be timed to the hundredth of a second. Two trials will be performed at each speed, and the average will be documented in meters per second. One-minute recoveries will be provided between trials.
Time frame: Baseline, 12 weeks
Change in Time for the Five Times Sit-to-Stand Test.
The five-time sit-to-stand test will be used to assess functional lower body strength. The participant will sit with arms folded across the chest and the back against the chair. On a verbal command, the participant will stand up and sit down five times as quickly as possible. Timing begins at the word go and ends when the buttocks touch the chair after the fifth repetition. One practice and two testing trials will be performed. Time will be measured in seconds.
Time frame: Baseline, 12 weeks
Change in the time required to complete the timed Up-and-Go Test.
Upon verbal cue, participants will stand up, walk around a cone placed three meters from the front edge of the chair and then returns to a seated position as quickly as possible. Time is measured in seconds.
Time frame: Baseline, 12 weeks
Change in Distance of the Seated Medicine Ball Throw.
Upper body power will be assessed using the Seated Medicine Ball Throw test. Participants will sit in an armless chair with their back against the chair back and throw a 6-pound medicine ball from the chest as far as possible at an approximate 45-degree angle. Participants will complete three recorded test attempts. The distance thrown in meters will be measured. There are no minimum or maximum possible values. Greater throwing distances indicate better upper body power.
Time frame: Baseline, 12 weeks
Change in Muscle Thickness using Ultrasound.
Muscle thickness will be assessed using B-mode ultrasonography. Three longitudinal-view images will be obtained for each muscle assessed. Muscle thickness will be measured by drawing a perpendicular line from the superficial aponeurosis to the deep aponeurosis at the thickest region of the muscle. Assessments will be performed on selected thigh and upper arm muscles. Muscle thickness is measured in centimeters (cm). Higher values indicate greater muscle thickness.
Time frame: Baseline, 12 weeks
Change in Muscle Quality using Ultrasound.
Muscle quality will be measured using a gray scale. Grayscale values range from 0 to 255 units, where lower values (darker pixels) indicate greater muscle tissue content and higher values (lighter pixels) indicate greater intramuscular fat. The muscle to be tested will be the thigh muscles and the back of your arm. Lower grayscale values indicate better muscle quality.
Time frame: Baseline, 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 3 months is below that.
Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.